XSHE
300109
Market cap1.20bUSD
Dec 05, Last price
17.50CNY
1D
0.69%
1Q
-7.70%
Jan 2017
-53.32%
IPO
15.31%
Name
Boai NKY Medical Holdings Ltd
Chart & Performance
P/E
24.32
P/S
5.30
EPS
0.72
Div Yield, %
5.94%
Shrs. gr., 5y
12.22%
Rev. gr., 5y
11.68%
Revenues
1.61b
+1.45%
Net income
350m
-29.07%
CFO
256m
-47.56%
Dividend
Jun 07, 20241.04 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boai NKY Medical Holdings Ltd. develops, manufactures, and sells polyvinylpyrrolidone (PVP) series products worldwide. The company offers KoVidone and PolyKoVidone line of products representing Povidone, Crospovidone, and Copovidone pharmaceutical excipients; OraRez line of PVM/MA copolymer and derivatives representing functional polymers for bioadhesive/mucoadhesive applications; KoVidone-1 broad spectrum biocidal, antifungal, and antiviral agents; and pharmaceutical solvents and intermediates. It also offers polymers, vinyl and vinyl ether compounds, PolyViscol, KoVidone I, WhiVidone, and PVPP. Its products are used in pharma, industrial, oral care, cosmetics, food and beverage, and other sectors. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to NKY medical holding Ltd. in March 2016. Boai NKY Medical Holdings Ltd. was founded in 1987 and is based in Heping, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||